IDRI & NanoPass Sign Agreement to Develop an Intradermal rvRNA-Based Zika Virus Vaccine

Zika remains a major public health threat, and its devastating neurological effects on newborns and infants are still being unraveled. More than ever, a vaccine is needed to protect against Zika virus, which is now considered on par with dangerous mosquito-borne viral diseases, like dengue, Japanese encephalitis or yellow fever. IDRI (Infectious Disease Research Institute) and NanoPass Technologies have signed a collaboration agreement to develop and test a new Zika vaccine based on a replicating viral RNA (rvRNA) construct administered intradermally using NanoPass's proprietary MicronJet600® microneedle device.

2017-03-05T14:17:21+00:00March 5th, 2017|

NanoPass Technologies to Present Newly Released Data on Intradermal Flu Vaccination

NanoPass technologies Ltd., a pioneer in the development of intradermal delivery devices for vaccines and cancer, allergy and diabetes immunotherapy will present new data on intradermal flu at the World Vaccine Congress (WVC) 2016 to be held October 10-12 in Barcelona, Spain. The newly released data, published on September 22, 2016[1] describes the results of a phase 1, open-label, randomized study comparing the immunogenicity and safety of various administration routes and doses of virosomal influenza vaccine in the elderly population. The study was conducted by Crucell Holland BV (a Janssen Company) in 6 centers in Belgium and Germany and included 370 healthy elderly subjects.

2017-03-05T14:18:21+00:00October 10th, 2016|

West Makes Investment in NanoPass Technologies

West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced a strategic investment in NanoPass Technologies Ltd. This investment will provide West with access to NanoPass' knowledge and expertise in the growing area of intradermal drug delivery and future collaboration opportunities to bring new products to market. West's investment will also allow NanoPass to advance its clinical development efforts and support the launch of its microneedle-based device for intradermal delivery of vaccines and drugs.

2017-02-12T12:12:24+00:00April 25th, 2016|

NanoPass Technologies to Supply MicronJet600™ Device to Immune Design for Use in ZVex-based Oncology Immunotherapy Products

NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600™, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform. The agreement will provide Immune Design non-exclusive access and supply for use of the device in all of its relevant cancer immunotherapy programs globally. Financial terms were not disclosed.

2017-03-05T14:19:26+00:00September 8th, 2015|

NanoPass Technologies will Present 8 Years of Clinical Experience With Its MicronJet600™ Device

NanoPass Technologies Ltd. ("NanoPass"), a pioneer in intradermal delivery solutions for vaccines and immunotherapies, announced today it will be delivering two oral presentations on the company's intradermal delivery device MicronJet600™ at the Skin Vaccination Summit in Lausanne, Switzerland on September 2-4. NanoPass's Chief Executive Officer, Yotam Levin, MD, will present 8 years of accumulated clinical data while the Company's Medical Director, Efrat Kochba, MD, will present the results of a recent intradermal iPV (inactivated polio vaccine) in HIV+ subjects.

2017-03-05T14:20:27+00:00August 31st, 2015|

Circassia and NanoPass strike up deal over intradermal device

Immunotherapy and vaccine specialist Circassia says its new license agreement with NanoPass Technologies will help its range of allergy products to thrive on the market. The UK based company inked a deal with NanoPass to use its intradermal injection delivery system, MicronJet microneedle, on all of its ToleroMune Allergy TCell Vaccines. The device enables the delivery of drugs directly into the skin where there is a higher concentration of immunologically active cells; the target for the vast majority of allergy therapies and certainly Circassia’s developmental range of allergy vaccines.

2017-03-05T14:21:18+00:00September 19th, 2011|